Relieves nasal and non-nasal symptoms. ANDA 78351, held by Natco Pharma USA. Desloratadine.
As of Nov 16, 2026, ANDA 78351 (Desloratadine), held by Natco Pharma USA, was first approved by FDA on Feb 10, 2012, with 2 approved supplements and 0 published complete response letters.
Desloratadine tablets are a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 12 years of age and older. Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 12 years of age and older. Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 12 years of age and older. 1.1 Seasonal Allergic Rhinitis Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desloratadine5MG · tablet;oral | Desloratadine | Rx |
| Oct 3, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 3, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 10, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters